The beta-adrenergic agonist L-644,969 was evaluated to determine its effects on growth performance and carcass composition of Friesian steers. L-644,969 is the R,R isomer of 6-amino [[(1-methyl-3-phenylpropyl) amino] methyl]-3-pyridine methanol dihydrochloride. Four groups of 18 steers, averaging 380 kg body weight, were individually given ad libitum access to a pelleted concentrate diet that contained either 0, .25, 1.0 or 4.0 ppm L-644,969 for the final 12 wk of the finishing period. Live weight gain was not affected by L-644,969, but feed consumption was linearly reduced (5.5, 6.3 and 15.7%; P less than .01) and feed conversion efficiency was linearly increased (16, 25 and 31%; P less than .01) relative to unmedicated controls, respectively. In addition, L-644,969 quadratically increased carcass weight (3.7, 9.3 and 8.5%; P less than .01) and dressing percentage (2.7, 7.9 and 7.9%; P less than .001). The proportion of trimmed fat in the carcass was quadratically reduced (14.5, 29 and 36%; P less than .001) and yield of lean meat quadratically increased (6.7, 13 and 15.6%; P less than .001). beta-adrenergic agonist treatment altered the distribution of lean meat such that a greater (P less than .001) proportion of the total lean was in the hind portion of carcasses from treated animals. Based on these findings, we suggest that L-644,969 may have utility as an agent to improve efficiency of production of lean beef.
Hypomagnesaemia may be encountered in various species, including man, but it is most commonly seen after moving cattle or sheep to fresh growing pasture. Field (1961) has shown that there may be a decrease in urinary excretion of magnesium under these conditions, even if the dietary intake is increased, so it appears that magnesium on such pasture cannot be absorbed normally, possibly because of interfering factors, or alternatively that there is an increase in endogenous faecal loss of magnesium. Very little is known about the factors involved in the absorption of magnesium in animals, and it was in an attempt to find some of these factors that the present work was undertaken. In vitro preparations of rat small intestine were used. METHODS The experimental animals were male rats of Wistar Hooded strain weighing 200-300 g and aged 10-20 weeks. Each rat was killed by a blow on the head. The abdomen was opened quickly and the small intestine cut about 10 cm from the pylorus. The mesentery was stripped off manually from the remainder of the small intestine which was cut into three segments. These segments were transferred to ice-cold bicarbonate saline of the following composition (mM): NaCl
Two studies are described which demonstrate the persistent activity of ivermectin injected subcutaneously into cattle at 200 micrograms/kg in preventing the establishment of induced infections with the gastrointestinal parasites Ostertagia ostertagi and Cooperia oncophora and the lungworm Dictyocaulus viviparus. These results indicated a reduction in mean worm count compared with the control group for O ostertagi of more than 99, 45 and 94 per cent with a seven, 14 or 21 day interval between treatment with ivermectin and the administration of infective larvae, respectively, in trial 1 and more than 99, more than 99 and 99 per cent at seven, 10 or 14 days, respectively, in trial 2. Corresponding values against C oncophora were 99, 0 and 45 per cent at seven, 14 and 21 days in trial 1 and more than 99, 84 and 31 per cent at seven, 10 and 14 days in trial 2. Against D viviparus, reduction in counts were more than 99, 98 and more than 99 per cent at seven, 14 and 21 days, respectively, in trial 1 and 100, 100 and 100 per cent at seven, 10 and 14 days, respectively, in trial 2. The relevance of these results to the build-up of infective larvae on pasture and infection in cattle is discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.